An observational study in Rheumatoid Arthritis, Osteoarthritis and Noninflammatory Degenerative Joint Disease, sponsored by Zimmer Biomet. Active, not recruiting at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by Zimmer Biomet · Observational
Among 59 studies in Arthritis, Rheumatoid by Zimmer Biomet — 4 open to participants now, 22 under way, none of them phase 3. Arthritis, Rheumatoid · Zimmer Biomet.
Among the 59 studies in Arthritis, Rheumatoid by Zimmer Biomet, this one is the 16th largest by planned enrollment of the 34 observational ones that give a count, is one of 4 that started in 2017, is one of 34 observational ones, reaches primary completion later than 12 of the 21 other live ones, and was the 26th registered.
3,332 studies on the registry are indexed under Arthritis, Rheumatoid; 443 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 59 studies in Arthritis, Rheumatoid by Zimmer Biomet are open now, in 5 countries. Recruiting first, the newest first:
Zimmer Biomet · Sites in Japan
Zimmer Biomet · Sites in United States
Zimmer Biomet · Sites in United States, Belgium, Italy and 1 more country
Zimmer Biomet · Sites in United States
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2017.
This study's planned enrollment of 160 is close to the median of 176 across 1,016 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 148 across the 25 interventional studies, 156 across the 34 observational. Of the 33 that completed or were terminated, 18 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.
6 of the studies in Arthritis, Rheumatoid by Zimmer Biomet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03409718Zimmer BiometDatabase Retrieval for the Comprehensive Shoulder | 2026-12 |
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT03404778Zimmer BiometComprehensive Reverse Shoulder Data Collection | 2026-12 |
| NCT05966519Zimmer BiometROSA Knee Intraoperative Planning Flexibility Study | 2027-01 |
Among the 59 studies in Arthritis, Rheumatoid by Zimmer Biomet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to obtain implant survivorship and clinical outcomes data for the commercially available G7 BiSpherical Acetabular Shell.
The G7 BiSpherical Acetabular Shell belongs to the G7 multi-bearing platform. It was developed to provide an additional surgical option for patients in need of a total hip replacement. The aim of the G7 BiSpherical Acetabular Shell is to increase hip function while reducing pain.
This study is a multicenter, prospective, non-randomized, non-controlled post market surveillance study involving orthopedic surgeons skilled in hip arthroplasty procedures. A minimum of 4 and a maximum of 5 sites will be involved in this study. This number of clinical centers will permit assessment of consistency among a multitude of investigators. 140-175 implants will be included into the study. Each site will be allowed to enroll 35 patients. All potential study subjects will be required to participate in the Informed Consent Process.
The safety and performance of the G7 BiSpherical Acetabular Shell will be assessed as following: implant survivorship based on revision with removal of the study device; safety based on incidence and frequency of adverse events; and clinical efficacy measured by overall pain and function, quality of life data and radiographic evaluation.
Patients in need of a Total Hip Arthroplasty (primary or revision) which receive the G7 BiSperical Acetabular Shell and who meet all of the inclusion and none of the exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria specific for patients receiving the G7 BiSpherical Shell with the G7 Freedom Constrained Liner:
Exclusion Criteria:
Absolute exclusion criteria include:
Relative exclusion criteria include:
Exclusion criteria specific for patients receiving the G7 BiSpherical Shell with the G7 Freedom Constrained Liner:
Subject in need of a THA who met the inclusion/exclusion criteria and received the G7 BiSpherical cup.
Implant survivorship is assessed counting the number of implant revisions
Time frame: 10 years
Clinical efficacy of the device is assessed using the Oxford Hip Score patient questionnaire
Time frame: 10 years
Clinical efficacy of the device is assessed using the Harris Hip Score patient questionnaire
Time frame: 10 years
Safety is assessed according to the number of complications which are collected via adverse event forms.
Time frame: 10 years
Started Dec 2017 (actual). Primary completion is estimated for Dec 2029, 144 months after the start.
Of 155 industry-sponsored observational studies under Arthritis, Rheumatoid, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 116. This study's planned 144 months is above that.
Counting every sponsor, half of 389 studies reached it within 50 months; a quarter within 25 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.